This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via ISI Web of Science (8) Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Li, J.-J. Articles by Hu, W.-L. Search for Related Content PubMed PubMed Citation Articles by Li, J.-J. Articles by Hu, W.-L. Social Bookmarking                   What's this?

Time Course of Rapid C-Reactive Protein Reduction by Pravastatin in Patients with Stable Angina

Renmin Hospital, Wuhan University School of Medicine, Wuhan, P.R. China, lijnjn{at}yahoo.com.cn

Chun-Hong Fang, MD

Department of Cardiology, Fu Wai Hospital, Peking Union Medical College, Beijing

Hai-Yan Qian, MD

Department of Cardiology, Fu Wai Hospital, Peking Union Medical College, Beijing

Wen-Lan Hu, MD

Department of Cardiology, Fu Wai Hospital, Peking Union Medical College, Beijing

The evidence has indicated that rapid reduction of inflammatory marker, such as C-reactive protein (CRP) could be achieved by administration of a statin. However, limited information is available in evaluating the short-term time course of CRP reduction in patients with coronary artery disease by use of a statin. Forty-two patients with stable angina were randomly assigned to 20 mg/d or 40 mg/d group of pravastatin. Blood samples were drawn at days 0, 1, and 14 for measuring lipid profile, CRP levels, and hepatic enzymes in all patients. The results showed that both doses of pravastatin induced significant reductions in median CRP levels and in mean CRP levels, respectively, at day 1 (20% in the 20 mg/d group and 17.6% in the 40 mg/d group; 15% in the 20 mg/d group and 10% in the 40 mg/d group) as well as at day 14 (28.6% in the 20 mg/d group and 33.3% in the 40 mg/d group; 25% in the 20 mg/d group and 22.8% in the 40 mg/d group) compared with baseline data without a dose-dependent manner. In addition, no changes were found at day 1 regarding lipid profile; however, both doses of pravastatin induced significant reductions in total cholesterol (TC, 22% and 30%), and low-density lipoprotein (LDL) cholesterol (30% and 40%) compared with baseline at 14 days. The higher dose of pravastatin resulted in significantly greater reductions in TC and LDL cholesterol compared with the 20 mg/d dose (p=0.05, p=0.01, respectively). A less significant reduction was observed in triglycerides level (16% and 24%) compared with TC and LDL cholesterol. There was no significant difference in mean high-density lipoprotein (HDL) cholesterol levels compared with baseline in both groups. These data suggested that a common daily dose of pravastatin resulted in rapid reduction of CRP within 24 hours and of lipid profile within 2 weeks, and the benefit to the vascular endothelium might occur quickly by reduction of CRP levels, which may be clinically important for patients in a high-risk subgroup, such as acute coronary artery disease.

Angiology, Vol. 57, No. 1, 1-7 (2006)
DOI: 10.1177/000331970605700101


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?